Curious about tirzepatide and what it means for patients? Tirzepatide, a combination GLP-1 and GIP agonist, was just approved by the Food and Drug Administration for the treatment of diabetes. Tirzepatide has also gained attention for its weight-reducing effects. However, how does tirzepatide compare to other GLP-1 agonists? Is tirzepaide a GameChanger for type 2 diabetes management? Learn more with host, Geoff Wall. 

 The GameChanger 
Tirzepatide is the first in its class to hit the market and has been shown to be as or more effective than semaglutide in glycemic control and weight reduction.  

 Show Segments 
00:00 – Introductions 
01:15 – Type 2 Diabetes & Treatment 
02:29 – Glucagon-like peptide-1 (GLP-1) Agonists 
03:04 – Glucose-dependent insulinotropic polypeptide (GIP) Agonist   
03:55 – Tirzepatide vs Semaglutide 
14:27 -  Tirzepatide vs Insulin 
21:15 – Retinopathy & Financial Considerations 
22:30 – Closing Remarks  

Host
Geoff Wall, PharmD., BCPS, FCCP, CGP 
Professor of Pharmacy Practice, Drake University 
Internal Medicine/Critical Care, UnityPoint Health 

References and Resources 

• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes 
• Once-Weekly Tirzeaptide Versus Once-Daily Insulin Degludec as Add-On to Metformin With or Without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): A Randomized, Open-Label, Parallel-Group, Phase 3 Trial  
• Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial 
• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial 

Redeem your CPE or CME here 

• CPE (Pharmacist)  
• CME (Physician)  

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a membership 
• Prescribers: Get a membership 

CE Information
Learning Objectives 

Upon successful completion of this knowledge-based activity, participants should be able to: 

1. Describe the safety and efficacy of tirzepatide compared to GLP-1 agonists 
2. Discuss the use of tirzepatide compared to basal insulin for blood glucose control 
3. Select a patient who may be a candidate for tirzepatide therapy 

0.05 CEU/0.5 Hr
UAN: 0107-0000-22-234-H01-P
Initial release date: 06/27/2022
Expiration date: 06/27/2023
Additional CPE and CME details can be found here. 

Follow CEimpact on Social Media:
LinkedIn
Instagram